Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a research report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a buy rating and set a $9.00 price objective on shares of Trevena in a research note on Tuesday, April 2nd.

Trevena Stock Up 1.3 %

NASDAQ:TRVN opened at $0.40 on Friday. The firm has a market cap of $7.30 million, a P/E ratio of -0.13 and a beta of 1.10. The company has a debt-to-equity ratio of 8.35, a quick ratio of 4.66 and a current ratio of 4.66. Trevena has a fifty-two week low of $0.30 and a fifty-two week high of $3.28. The firm has a 50-day simple moving average of $0.51 and a two-hundred day simple moving average of $0.58.

Institutional Trading of Trevena

A number of large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Trevena by 51.8% in the first quarter. Renaissance Technologies LLC now owns 70,532 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 24,080 shares during the period. Dimensional Fund Advisors LP purchased a new position in shares of Trevena in the fourth quarter worth approximately $40,000. Jane Street Group LLC boosted its holdings in shares of Trevena by 166.2% in the first quarter. Jane Street Group LLC now owns 45,330 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 28,303 shares during the last quarter. Jump Financial LLC purchased a new position in Trevena during the third quarter valued at approximately $27,000. Finally, Virtu Financial LLC purchased a new position in Trevena during the second quarter valued at approximately $70,000. 13.56% of the stock is currently owned by institutional investors.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.